News
-
-
-
PRESS RELEASE
Multitude SE announces its intention to voluntarily redeem all outstanding senior bonds due 2025
Multitude SE announces intention to redeem all outstanding senior bonds due 2025 in accordance with terms and conditions, conditional upon subsidiary's bond issuance. Bonds to be de-listed post-redemption -
PRESS RELEASE
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
Formycon initiates clinical program for FYB206, a biosimilar candidate for Keytruda, targeting immuno-oncology. Phase I and III trials underway to assess safety, efficacy, and PK equivalence -
-
-
-
-
PRESS RELEASE
Multitude Capital Oyj successfully places EUR 80 million in senior guaranteed unsecured bonds
Multitude Capital Oyj successfully places EUR 80 million in senior guaranteed unsecured bonds with strong investor demand. Bonds to be listed on regulated market. Fitch Ratings to assign 'B+' rating -